Clinical Trial Update: Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer [Phase 2]

View source ↗

Summary

This document summarizes an ongoing Phase 2 clinical trial at MD Anderson evaluating whether genetic testing can predict tumor response in patients with Stage I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING